The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC).
J. Lu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
H. Deng
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
R. Tang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
C. Hsu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
H. L. Kindler
Consultant or Advisory Role - Abbott Laboratories; Amgen; Bristol-Myers Squibb; Clovis Oncology; Merck; Otsuka; Roche
C. S. Fuchs
Consultant or Advisory Role - Alnylam; Amgen; AstraZeneca; Bristol-Myers Squibb; Genentech; ImClone Systems; Merck; POZEN; Roche
J. L. Gansert
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
S. Bray
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
S. S. Suzuki
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
E. Loh
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
M. Zhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen